AU710823B2 - Valaciclovir tablets containing colloidal silicon dioxide - Google Patents

Valaciclovir tablets containing colloidal silicon dioxide Download PDF

Info

Publication number
AU710823B2
AU710823B2 AU44534/96A AU4453496A AU710823B2 AU 710823 B2 AU710823 B2 AU 710823B2 AU 44534/96 A AU44534/96 A AU 44534/96A AU 4453496 A AU4453496 A AU 4453496A AU 710823 B2 AU710823 B2 AU 710823B2
Authority
AU
Australia
Prior art keywords
tablet
valaciclovir
silicon dioxide
lubricant
colloidal silicon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44534/96A
Other languages
English (en)
Other versions
AU4453496A (en
Inventor
Barry Howard Carter
Lloyd Gary Tillman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768317&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU710823(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of AU4453496A publication Critical patent/AU4453496A/en
Application granted granted Critical
Publication of AU710823B2 publication Critical patent/AU710823B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU44534/96A 1995-01-20 1996-01-19 Valaciclovir tablets containing colloidal silicon dioxide Ceased AU710823B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9501127 1995-01-20
GBGB9501127.6A GB9501127D0 (en) 1995-01-20 1995-01-20 Tablet
PCT/GB1996/000111 WO1996022082A1 (en) 1995-01-20 1996-01-19 Valaciclovir tablets containing colloidal silicon dioxide

Publications (2)

Publication Number Publication Date
AU4453496A AU4453496A (en) 1996-08-07
AU710823B2 true AU710823B2 (en) 1999-09-30

Family

ID=10768317

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44534/96A Ceased AU710823B2 (en) 1995-01-20 1996-01-19 Valaciclovir tablets containing colloidal silicon dioxide

Country Status (38)

Country Link
US (1) US5879706A (enExample)
EP (1) EP0806943B1 (enExample)
JP (1) JP3350055B2 (enExample)
KR (1) KR100412298B1 (enExample)
CN (2) CN1313081C (enExample)
AP (1) AP666A (enExample)
AT (1) ATE190483T1 (enExample)
AU (1) AU710823B2 (enExample)
BG (1) BG63187B1 (enExample)
BR (1) BR9606769A (enExample)
CA (1) CA2210891C (enExample)
CY (1) CY2182B1 (enExample)
CZ (1) CZ296514B6 (enExample)
DE (1) DE69607146T2 (enExample)
DK (1) DK0806943T3 (enExample)
EA (1) EA000276B1 (enExample)
EE (1) EE03336B1 (enExample)
ES (1) ES2145425T3 (enExample)
FI (1) FI119722B (enExample)
GB (1) GB9501127D0 (enExample)
GE (1) GEP20022752B (enExample)
GR (1) GR3033677T3 (enExample)
HU (1) HU226131B1 (enExample)
IL (1) IL116830A (enExample)
IN (1) IN181318B (enExample)
MY (1) MY126346A (enExample)
NO (1) NO311488B1 (enExample)
NZ (1) NZ298846A (enExample)
OA (1) OA10500A (enExample)
PL (1) PL185307B1 (enExample)
PT (1) PT806943E (enExample)
RO (1) RO118175B1 (enExample)
SK (1) SK282030B6 (enExample)
TR (1) TR199700657T1 (enExample)
UA (1) UA68325C2 (enExample)
UY (2) UY25774A1 (enExample)
WO (1) WO1996022082A1 (enExample)
ZA (1) ZA96448B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet
ZA97400B (en) * 1996-01-19 1997-11-13 Glaxo Group Ltd Valaciclovir.
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
AR017512A1 (es) * 1997-08-22 2001-09-12 Smithkline Beecham Corp Tabletas de metilcelulosa rapidamente desintegrables para administracion por via oral y procedimiento para prepararlas
BR9916361A (pt) * 1998-12-18 2002-11-05 Abbott Lab Forma de dosagem de tabletes de liberação controlada, formulação de tablete de liberação controlada, composição granular para prensagem em uma forma de dosagem de tablete de liberação controlada, e, métodos para preparar uma composição granular, para preparar uma forma de dosagem de tabletes de liberação controlada de divalproex sódio e para tratar epilepsia
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
UA75135C2 (en) * 2001-05-01 2006-03-15 Pfizer Prod Inc Dry granulation method for manufacturing pharmaceutical composition containing tetrahydronaphthalene-2-ol derivative and low dosage tablet compositions
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
JP2005511612A (ja) * 2001-11-05 2005-04-28 グラクソ　グループ　リミテッド 塩酸バラシクロビルの無水結晶形
JP2005508993A (ja) * 2001-11-14 2005-04-07 テバ ファーマシューティカル インダストリーズ リミティド バラシクロビルの合成及び精製
GB0203296D0 (en) * 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
GB0209265D0 (en) * 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20050070711A1 (en) * 2002-10-16 2005-03-31 Igor Lifshitz Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20040109889A1 (en) * 2002-12-04 2004-06-10 Bunick Frank J. Surface treatment composition for soft substrates
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
KR100871621B1 (ko) * 2003-06-02 2008-12-02 테바 파마슈티컬 인더스트리즈 리미티드 발라시클로비르 히드로클로라이드의 신규한 결정질 형태
US7632521B2 (en) * 2003-07-15 2009-12-15 Eurand, Inc. Controlled release potassium chloride tablets
EP1663182B2 (en) 2003-09-12 2019-11-20 Amgen Inc. RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
EP1541133B1 (en) * 2003-12-09 2005-08-10 Helm AG Pharmaceutical formulation of valaciclovir
US7344907B2 (en) * 2004-11-19 2008-03-18 International Business Machines Corporation Apparatus and methods for encapsulating microelectromechanical (MEM) devices on a wafer scale
KR101116747B1 (ko) 2004-12-06 2012-02-22 에스케이케미칼주식회사 안정성이 개선된 말레인산 암로디핀 약제 조성물
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
US7846937B2 (en) * 2005-05-25 2010-12-07 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
EP1746098A1 (en) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
WO2007090595A1 (en) * 2006-02-06 2007-08-16 Fidia Pharmaceutici S.P.A. Solid formulations of valacyclovir hydrochloride
US20090312439A1 (en) * 2006-05-10 2009-12-17 Ralph Hofmann Use of roll compacted pyrogenically produced silicon dioxide in pharmaceutical compositions
PL2037887T3 (pl) * 2006-05-31 2011-03-31 Vertex Pharma Doustne preparaty o kontrolowanym uwalnianiu inhibitora enzymu konwertującego interleukinę 1 beta
US20090291136A1 (en) * 2006-07-11 2009-11-26 Lek Pharmaceuticals D.D. Multiple Unit Tablets
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
ITRM20080027A1 (it) * 2008-01-18 2009-07-19 Maria Balestrieri Uso di aciclovir per il trattamento delle condilomatosi.
US20100124560A1 (en) * 2008-11-14 2010-05-20 Mcneil Ab Multi portion intra-oral dosage form and use thereof
US8513261B2 (en) * 2009-03-13 2013-08-20 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
CH703348A1 (de) * 2010-06-29 2011-12-30 Mepha Gmbh Zusammensetzungen mit hohem Wirkstoffanteil an pharmazeutisch aktiven Substanzen.
GB2515486A (en) * 2013-06-24 2014-12-31 Kraft Foods R & D Inc Soluble Beverage Ingredients
KR101497508B1 (ko) * 2013-12-20 2015-03-03 한국유나이티드제약 주식회사 펠라고니움 시도이데스 추출물 및 규산 화합물을 포함하는 고형 제제 및 이의 제조 방법
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2020049536A1 (en) * 2018-09-07 2020-03-12 Jubilant Generics Limited Pharmaceutical compositions of valacyclovir or its pharmaceutically acceptable salts thereof
CN110279667B (zh) * 2019-07-30 2023-02-10 珠海润都制药股份有限公司 一种盐酸伐昔洛韦片及其制备方法
US20230201234A1 (en) * 2020-06-01 2023-06-29 Shilpa Medicare Ltd Fast dispersible pharmaceutical composition comprising capecitabine
CN116528853B (zh) * 2020-12-01 2026-03-20 信达生物科技有限公司 包含1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸的口服制剂及其制备方法
WO2024047094A1 (en) * 2022-08-31 2024-03-07 Astrazeneca Ab Pharmaceutical formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1259924A (en) * 1985-03-25 1989-09-26 Wallace E. Becker Pharmaceutical tableting method
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
DE68903605T2 (de) * 1988-05-04 1993-04-01 Smith Kline French Lab Kautablette.
AU653203B2 (en) * 1991-01-30 1994-09-22 Wellcome Foundation Limited, The Water-dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
GB9317146D0 (en) * 1993-08-18 1993-10-06 Wellcome Found Therapeutic combinations
GB9501127D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Tablet

Also Published As

Publication number Publication date
ZA96448B (en) 1996-08-07
EP0806943B1 (en) 2000-03-15
AP666A (en) 1998-08-24
EA199700123A1 (ru) 1997-12-30
HUP9801872A2 (hu) 1999-10-28
KR19980701524A (ko) 1998-05-15
PT806943E (pt) 2000-08-31
EP0806943A1 (en) 1997-11-19
MX9705459A (es) 1997-10-31
DE69607146D1 (de) 2000-04-20
IL116830A (en) 2000-02-29
WO1996022082A1 (en) 1996-07-25
CN1313081C (zh) 2007-05-02
CZ296514B6 (cs) 2006-03-15
FI973062L (fi) 1997-09-18
AP9701057A0 (en) 1997-10-31
KR100412298B1 (ko) 2004-04-21
PL321361A1 (en) 1997-12-08
IN181318B (enExample) 1998-05-09
OA10500A (en) 2002-04-10
BG101831A (en) 1998-04-30
CN1494898A (zh) 2004-05-12
BR9606769A (pt) 1997-12-30
EA000276B1 (ru) 1999-02-25
GR3033677T3 (en) 2000-10-31
HU226131B1 (en) 2008-05-28
FI119722B (fi) 2009-02-27
NO973327D0 (no) 1997-07-18
FI973062A0 (fi) 1997-07-18
CZ229297A3 (cs) 1998-02-18
NO973327L (no) 1997-09-16
AU4453496A (en) 1996-08-07
UY25778A1 (es) 2000-08-21
CY2182B1 (en) 2002-08-23
EE03336B1 (et) 2001-02-15
DE69607146T2 (de) 2000-09-21
SK282030B6 (sk) 2001-10-08
CN1179100A (zh) 1998-04-15
MY126346A (en) 2006-09-29
UY25774A1 (es) 2000-10-31
HK1002851A1 (en) 1998-09-25
NZ298846A (en) 1998-06-26
DK0806943T3 (da) 2000-07-24
IL116830A0 (en) 1996-05-14
BG63187B1 (bg) 2001-06-29
JP3350055B2 (ja) 2002-11-25
ATE190483T1 (de) 2000-04-15
HUP9801872A3 (en) 2001-02-28
GB9501127D0 (en) 1995-03-08
US5879706A (en) 1999-03-09
CA2210891C (en) 2009-05-19
SK96497A3 (en) 1998-01-14
JPH10512564A (ja) 1998-12-02
RO118175B1 (ro) 2003-03-28
GEP20022752B (en) 2002-08-26
CA2210891A1 (en) 1996-07-25
CN1131026C (zh) 2003-12-17
TR199700657T1 (xx) 1998-02-21
UA68325C2 (en) 2004-08-16
ES2145425T3 (es) 2000-07-01
NO311488B1 (no) 2001-12-03
PL185307B1 (pl) 2003-04-30

Similar Documents

Publication Publication Date Title
AU710823B2 (en) Valaciclovir tablets containing colloidal silicon dioxide
AP662A (en) Anhydrous crystalline valaciclovir hydrochloride.
AU722304B2 (en) Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
HK1002851B (en) Valaciclovir tablets containing colloidal silicon dioxide
MXPA97005459A (en) Valaciclovir tablets containing silicon dioxide color
HK1003055B (en) Guanine derivative
HK1003055A1 (en) Guanine derivative